{"id":"ikh-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IKH-01 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, but the exact molecular details of IKH-01's interaction with the SGLT2 receptor are not well understood.","oneSentence":"IKH-01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:17.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00746096","phase":"PHASE3","title":"Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2008-09","conditions":"Dysmenorrhea","enrollment":115},{"nctId":"NCT01253824","phase":"PHASE3","title":"Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2011-01","conditions":"Healthy","enrollment":14},{"nctId":"NCT01129102","phase":"PHASE3","title":"Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2010-05","conditions":"Dysmenorrhea","enrollment":215}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["norethisterone and ethinyl estradiol"],"phase":"phase_3","status":"active","brandName":"IKH-01","genericName":"IKH-01","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IKH-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}